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ABSTRACT
Primary Purpose. Formation of ascites and pleural
effusion (PE) is a common problem for patients with
advanced-stage cancer. These fluid accumulations cause
severe symptoms such as abdominal distention, shortness
of breath, cachexia, anorexia, and fatigue. Preclinical
models have demonstrated that vascular endothelial
growth factor (VEGF) plays a pivotal role in the accu-
mulation of malignant PE or ascites. This study investi-
gated whether blockade of VEGF activity would reduce
biological activity of PE and ascites on endothelial cells of
cancer patients.
Patients and Methods. The activity of VEGF in PE
and ascites of 58 patients (39 with PE and 19 with
ascites) was measured. An endothelial cell prolifera-
tion assay with human umbilical vein endothelial cells
was used to determine the biological activity of ascites
and PE.
Results. VEGF concentrations ranged from 67-6,245
pg/ml. A significantly higher concentration of VEGF
was detected in the ascites and PE of patients with 
cancer (median, 1,290 pg/ml) than in patients with non-
malignant disease (median, 250 pg/ml; p = 0.02). Of the
58 PE and ascites samples, 41 were biologically active,
based on a two- to fourfold stimulation of endothelial
cell proliferation in 72 hours. VEGF concentrations
were significantly higher in the biologically active sam-
ples compared with the 17 nonactive samples (2,056
pg/ml versus 771 pg/ml; p = 0.02). Coincubation of the
samples with either a neutralizing polyclonal antibody
against VEGF or SU5416, a small molecule inhibitor of
the VEGF receptor Flk-1/KDR, inhibited endothelial
cell proliferation by 66% and 100%, respectively. The
inhibition caused by the antibody and that caused by
SU5416 correlated significantly (r = 0.8, p < 0.001).
Conclusion. We conclude that malignant ascites and
PE contain high levels of biologically active VEGF. This
study strongly supports the hypothesis that blockade of
VEGF, such as that afforded by SU5416, may benefit
cancer patients with recurrent ascites or PE formation.
The Oncologist 2000;5(suppl 1):45-50
The Oncologist 2000;5(suppl 1):45-50 www.TheOncologist.com
Correspondence: H.M. Pinedo, M.D., Ph.D., Head, Department of Medical Oncology, University Hospital “Vrije Universiteit,”
Postbus 1007 MB, Amsterdam, The Netherlands. Telephone: 31-20-4444300; Fax: 31-20-4444355; e-mail: hm.pinedo@azvu.nl
Accepted for publication February 22, 2000. ©AlphaMed Press 1083-7159/2000/$5.00/0
INTRODUCTION
The formation of ascites and pleural effusion (PE) in
patients with advanced-stage cancer is a difficult problem in
clinical oncology. Ascites and PE cause serious symptoms
including abdominal distention, shortness of breath,
cachexia, anorexia, and fatigue. The formation of ascites and
PE mostly occurs in advanced-stage disease. Currently, alter-
natives for cytotoxic therapy against ascites and PE include
diuresis, salt restriction, pleurodesis, and peritoneovenous
shunts [1-6].
The etiology of PE and ascites has traditionally been
attributed to insufficient lymph drainage caused by tumor
spread into draining lymph vessels [7]. However, in 1986,
Senger et al. suggested an alternative possibility [8]. They
isolated vascular permeability factor (VPF) from ascites in
tumor-bearing animals and hypothesized that this factor
was responsible for the fluid accumulations. A few years
later, vascular endothelial growth factor (VEGF) was dis-
covered as a potent angiogenesis stimulator and recognized
to be VPF [9, 10].
Five different VEGF mRNAs have been detected encod-
ing the isoforms VEGF121, VEGF145, VEGF165, VEGF189, and
VEGF206 [11]. The receptors for VEGF are mainly confined to
the endothelial cells and belong to the tyrosine kinase receptor
family [11]. Two specific endothelial cell receptors for VEGF
have been identified, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-
1/KDR) [12-15]. Flk-1/KDR appears to be the receptor that is
mainly involved in the angiogenesis process [15-17].
Several preclinical in vivo studies [18-20] have clearly
demonstrated that ascites and PE formation induced by
tumor cells contain high concentrations of VEGF. Blockade
of the VEGF activity in mice using anti-VEGF antibodies
[21, 22] or VEGF receptor tyrosine kinase inhibitors [20]
led to significantly reduced fluid accumulations. In addi-
tion, use of anti-VEGF antibodies was associated with pro-
longed survival in MM2 breast carcinoma-bearing mice
compared with controls [21].
In clinical studies [23-25], high concentrations of
VEGF have been found in malignant PE and ascites, while
lower concentrations were detected in ascites and PE from
nonmalignant diseases such as congestive heart failure [25]
or liver cirrhosis [23].
These findings have prompted the hypothesis that anti-
VEGF therapy could block ascites and PE formation in can-
cer patients. However, no data have been reported that VEGF
in ascites and PE is biologically active. Therefore, we studied
the concentrations of VEGF in ascites and PE of patients with
malignancies, investigated the biological activity of these
specimens, and evaluated whether an anti-VEGF antibody
and a VEGF receptor tyrosine kinase inhibitor, SU5416
(SUGEN, Inc.; South San Francisco, CA), could block VEGF
activity. Biological activity was tested in an endothelial cell
proliferation assay. 
PATIENTS AND METHODS
Patients
PE and ascites were aspirated on clinical indication
from 58 patients, 11 patients without a malignancy and 47
with a malignancy. Malignancies included gastrointestinal
tumors (n = 10), lung tumors (n = 7), breast cancers (n = 9),
and ovarian cancers (n = 6), and 15 patients had melanoma,
soft tissue sarcoma, mesothelioma, or unknown primaries.
The 11 patients with nonmalignant disease suffered from
an infection, heart failure, autoimmune disease, or a benign
tumor such as a thymoma. Upon informed consent from
patients, ~10 ml of aspirations from PE or ascites were
immediately centrifuged at 3,500 rpm, and the supernatant
was stored at –80°C. Because ascites and PE formation
recurred in some patients, repeated aspirations were neces-
sary; up to four different samples from a single patient
were stored.
Methods
VEGF Concentrations
VEGF concentrations were measured with a quantitative
sandwich enzyme immunoassay (R&D Systems; Abingdon,
UK), according to the manufacturer’s instructions.
Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVECs)
were obtained by a standard procedure [26]. Endothelial cells
were cultured on fibronectin (10 m g/ml)-coated plates in
endothelial cell growth medium (M199 containing 10%
human serum, 10% fetal calf serum [FCS], 5 units/ml heparin,
1% penicillin [200 U/ml], 1% streptomycin [200 m g/ml], 1%
glutamine [290 g/l], and 50 m g/ml endothelial cell growth fac-
tor [ECGF] derived from bovine hypothalamus). Only cells
from the first three cell passages were used in all experiments. 
Proliferation Assay
HUVECs were plated in a density of 3,000 cells/well on
precoated 96-well plates in 100 m l endothelial cell medium
containing 5% FCS and 5% newborn calf serum with no
ECGF added. The following day, 100 m l of PE or ascites
(concentration range, 3%-100%) in endothelial cell growth
medium without serum were added. After 72 h, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)
assay test was performed according to standard procedures. In
each, experimental conditions were tested in triplicate.
Inhibition Experiments
Endothelial cell proliferation stimulated by PE or ascites
in a final concentration of 25% was either coincubated with a
polyclonal antibody against VEGF (1 m g/ml, R&D Systems)
or with SU5416 in a concentration of 1 m M. SU5416 was pro-
vided by SUGEN, Inc. A polyclonal rabbit IgG was used as a
negative control for the polyclonal antibody against VEGF. 
Statistical Analysis
Statistical analysis was performed with SPSS software
(SPSS, Inc.; Chicago, IL). For the correlation coefficient, the
Spearman rank correlation test was used. Statistical differences
were calculated with the t test.
RESULTS
VEGF Concentrations
VEGF concentrations were significantly higher in 
the 19 cancer patients with ascites and the 28 cancer patients
with PE (median, 1,290 pg/ml; range, 67-6,245 pg/ml) com-
pared with 11 patients with nonmalignant disease (median, 250
pg/ml; range, 90-2,167 pg/ml; p = 0.02). Total protein concen-
trations did not differ significantly (p = 0.7) in patients with a
malignant versus nonmalignant disease. VEGF and bFGF con-
centrations did not differ significantly between malignancies.
Proliferation Assay
In a 72-hour proliferation assay, samples with high
VEGF concentrations increased the proliferation rate of
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HUVECs to a fourfold maximum. A rather weak, but sig-
nificant, correlation between the VEGF concentration and
the induction of proliferation was found (r = 0.4, p < 0.01).
Figure 1 depicts a representative experiment with six sam-
ples of PE and ascites. The samples that induced a two- to
fourfold proliferation contained significantly higher VEGF
concentrations compared with the inactive samples (Fig. 2).
Inhibition Assay
When 25% of the samples were coincubated with either
a blocking antibody against VEGF or the VEGF tyrosine
kinase inhibitor SU5416, up to 100% of the biological
activity of these fluids was blocked. Anti-VEGF antibody
and SU5416 in concentrations of 1 m g/ml and 1 mM,
respectively, were used because these concentrations
blocked the proliferation of 25 ng/ml of recombinant
human VEGF but had no effect on recombinant human
bFGF (12.5 ng/ml)-induced proliferation. In the prolifera-
tion assay, the inhibitory effect of the anti-VEGF antibody
correlated highly with the inhibitor effect of SU5416 (r =
0.8, p < 0.001, Fig. 3).
DISCUSSION
The results of this study strongly support the hypoth-
esis that VEGF is important for the formation of ascites
and PE in patients with cancer, confirmed that ascites and
PE from cancer patients contain higher VEGF concentra-
tions than those obtained from patients with nonmalignant
disease, and also showed that this VEGF is biologically
active in a proliferation assay of HUVECs. Therefore, it
may be expected that in a subpopulation of patients with
ascites or PE containing high concentrations of VEGF,
this endothelial growth factor is at least partly responsible
for the fluid accumulation. The VEGF tyrosine kinase
receptor blocker SU5416 could inhibit the proliferation of
HUVECs induced by ascites and PE to a similar extent as
a blocking antibody against VEGF. We therefore conclude
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Figure 1. Stimulation of human vascular endothelial cells by ascites
and pleural effusion (PE). The effect on proliferation of coincubation
of 0%-50% of ascites or PE samples with HUVECs for 72 hours was
measured by 3(4,5-dimethyliazol-2-y-l)-2,5-diphenyltetrazolium bro-
mide. A zero- to fourfold proliferation was induced by these fluids and
correlated with their VEGF contents (p = 0.05). A representative
experiment is shown in this figure. OD = optical density.
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Figure 2. Effect of ascites or pleural effusion on human vascular
endothelial cell proliferation relative to vascular endothelial growth
factor (VEGF) content. The difference between VEGF concentrations
in samples that induced a two- to fourfold proliferation (+) versus sam-
ples that were inactive in the proliferation assay (–) compared with
baseline proliferation is shown. The VEGF concentrations were signif-
icantly different between the active and inactive samples (p = 0.02).
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Figure 3. Correlation between inhibitory effects of SU5416 and
the anti-vascular endothelial growth factor (VEGF) antibody on
human vascular endothelial cell proliferation. A significant corre-
lation (r = 0.8, p < 0.001) was found between the relative inhibition
(%) of ascites/PE-induced human umbilical vein endothelial cell
(HUVEC) proliferation by SU5416 and by the anti-VEGF antibody
(anti-VEGFmAb).
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that treatment with SU5416, or another agent that blocks
the VEGF pathway, may benefit patients with recurrent
ascites and PE formation.
Although VEGF concentrations are significantly higher
in effusions of patients with malignant disease, the overlap in
the concentration of VEGF between malignant and nonma-
lignant disease is rather large [25]. Therefore, VEGF con-
centration may not be a useful parameter for discriminating
between nonmalignant and malignant disease.
Ascites and PE formation have often been assumed to
be due to inadequate lymph drainage resulting from infil-
tration of tumor tissue into the lymphatics [7]. However, if
blockage of the lymphatic vessels were the primary cause,
the pleural fluids would be transudate rather than exudate
(high protein content), as seen in fluids associated with
malignancies [25]. Our data support this statement because
high levels of VEGF in these fluid accumulations are bio-
logically active in vitro and thus presumably active in vivo.
Although it is uncertain that VEGF is the primary cause of
malignant ascites and PE formation, it can be assumed that
VEGF at least contributes significantly.
In addition to VEGF, other cytokines and factors, includ-
ing lysophosphatidic acid [27] and interleukin 8 [28], have
been found in high concentrations in malignant ascites and/or
PE. However, these factors have not been tested for their in
vitro activity on endothelial cells. VEGF appears to be the
only factor that induces permeability in vivo and is present in
high amounts in these fluids.
It is noteworthy that in the study by Thickett et al. [24],
VEGF concentrations in PE were higher in empyema than
in malignant disease (4,651 pg/ml versus 2,500 pg/ml,
respectively). In our study, PE obtained from one patient
with empyema also contained a high concentration of
VEGF (1,637 pg/ml). Additionally, among the other
patients with nonmalignant diseases, one patient with tuber-
culosis infection also had a high VEGF concentration
(2,167 pg/ml). Both empyema and tuberculosis, when left
untreated, cause fibrotic lesions [29-31]. In tumors, VEGF
has been shown to induce endothelial fenestration [32, 33]
that can lead to extravascular fibrin deposition [11, 34, 35];
this may also be true for the fibrotic lesions observed in
empyema and tuberculosis.
The permeability effect of VEGF is expected to play an
important role in the angiogenic process of solid tumors and
in the formation of ascites and PE. In addition, malignant
cysts formed in ovarian cancer contained elevated levels of
VEGF (38.5 ± 8.2 ng/ml) [36]. Fluid cavities of soft tissue
sarcomas also contained VEGF (median, 18 ng/ml; range,
0.3-345 ng/ml) [37], which may suggest an important role
for VEGF. VEGF also seems to be involved in extravascu-
lar fluid accumulations in rheumatoid arthritis [38]. High
levels of VEGF were detected in the synovial fluids of
rheumatoid joints.
The permeability activity of VEGF is based on the ini-
tial in vivo findings of Senger et al. [8] and on subsequent
in vivo experiments. To the best of our knowledge, no
study to date has been published showing that VEGF
induces permeability of endothelial cells for plasma pro-
teins in vitro. We developed an in vitro permeability assay
for plasma proteins (30-70 kD) in a transwell system with
a confluent layer of HUVECs and used it to test the activ-
ity of recombinant human VEGF (data not shown). We
failed to demonstrate a reproducible permeability effect of
recombinant human VEGF in vitro, indicating that an
essential factor or cofactor of the in vivo situation is miss-
ing in this assay. In a study by Wang et al. [39], VEGF
induced permeability in vitro, but permeability was only
observed for [14C] sucrose (molecular weight, 400 D); no
permeability was detected with radiolabeled albumin. The
implication of VEGF-induced leakage of small molecules
is unclear, since the importance of VEGF-induced perme-
ability in vivo is related to larger plasma proteins. It is too
early to make any definite conclusions; further research is
needed to explore the essential difference between the in
vivo and in vitro situations.
Finally, the correlation between the inhibitory effects of
the anti-VEGF antibody and SU5416 strongly suggests that
the VEGF pathway is mainly responsible for the PE/ascites-
induced proliferation of the HUVECs. Because SU5416
inhibited up to 100% of the proliferation induced by these
samples, SU5416 treatment may be of interest for patients
with recurrent ascites and PE. Since outpatient treatment
for patients with advanced-stage disease is often difficult,
the development of an oral formulation may have additional
benefit in the management of this patient population.
In conclusion, one may expect that in a subpopulation
of patients with malignant ascites or PE containing high
concentrations of VEGF, this growth factor is responsible
for the fluid accumulation and that these patients may
benefit from anti-VEGF therapy. Just recently, we initi-
ated a clinical study in which the VEGF tyrosine kinase
inhibitor SU5416 will be tested for its activity against
recurrent PE or ascites formation. In addition to the main
question of whether prolonged treatment with SU5416
prevents or inhibits reaccumulation of ascites or PE in
cancer patients, two other interesting questions need to be
answered in this study. The first is whether the effect of
VEGF on reaccumulation of malignant fluid can be used
as a marker for the biological activity of SU5416 in the
patient. The second question is whether the VEGF mea-
surements will predict the effect of SU5416 in patients
with recurrent fluid formations.
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